ADAM metallopeptidase domain 29Genealiases: CT73 · svph1
Q-omics provides the consensus-scored ADAM29 profile across patient tissues and cancer cell-line models. ADAM29 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, ADAM29 is differentially expressed in 8, with the highest sampling consensus in LUAD. Additionally, ADAM29 RNA expression shows 14,131 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight MESO, LUAD, and LSCC as cancer lineages where ADAM29 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ADAM29 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ADAM29 survival associations across molecular data types. ADAM29 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ADAM29 RNA expression–survival associations across cancer types. High ADAM29 expression shows unfavorable associations in MESO, UVM, KICH and UCS, but favorable associations in LGG and BRCA. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .002). Together, the overview and detailed table identify MESO as the clearest survival context for ADAM29 RNA expression.
This table summarizes ADAM29 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in LUAD for RNA.
This table ranks reproducible tumor–normal expression differences for ADAM29. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ADAM29 shows lower tumor expression in LUAD, LUSC, UCEC and BLCA and higher tumor expression in HNSC and KIRC. The LUAD box plot shows higher ADAM29 RNA expression in normal versus tumor tissue (log2 FC = −0.202, t-test p < 0.001).
This table shows molecular features associated with ADAM29 in patient tissues and cancer cell lines. In patient samples, ADAM29 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, ADAM29 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Lymphoma, while CRISPR and shRNA rows add functional-dependency signals in LUNG_SCLC and LARGE_INTESTINE.
